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Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by
surface expression of CXCR4. This receptor for stromal cell-derived factor-1α (SDF-
1α) is cleaved by dipeptidyl peptidase-4 (DPP-4). Tang cell levels were investigated in
people with type 2 diabetes mellitus (T2DM) compared with matched healthy con-
trols and after treatment with the DPP-4 inhibitor Linagliptin. People with T2DM
were randomized to 5 mg/day Linagliptin (n = 20) or placebo (n = 21) for 26 weeks.
Tang cell frequency was identified in peripheral blood mononuclear cells
(CD3+CD31+CXCR4+) and levels of endothelial progenitor cells (EPCs)
(CD34+CD133+KDR+) were also assessed in whole blood. Circulating Tang cell levels
were significantly lower in people with T2DM compared with the healthy control
group. SDF-1α levels increased significantly in Linagliptin-treated people with T2DM
compared to placebo, and a trend was observed in change of Tang cell levels, while
EPC count did not change. In conclusion, circulating Tang cell levels were consider-
ably lower in people with T2DM, while a trend was observed in recruitment of Tang
cells after 26 weeks of treatment with Linagliptin. These data suggest that DPP-4
inhibitors may potentially exert beneficial effects on bone marrow-driven vascular
repair.
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1 | INTRODUCTION
Type 2 diabetes mellitus (T2DM) is associated with an increased car-
diovascular disease (CVD) risk. The underlying pathogenesis of CVD
in T2DM is incompletely understood. Recent data suggest that the
enzyme dipeptidyl peptidase-4 (DPP-4) constitutes a link between
T2DM and cardiovascular (CV) risk.1
Several pathways involved in CVD may be targeted by inhibiting
DPP-4. This changes the proportion of lymphocyte subpopulations2,3
and degrades multiple chemokines, such as stromal cell-derived factor
1α (SDF-1α, also known as CXCL12) and chemokine (C-C motif) ligand
5 (CCL5), and blocks binding to their major receptors CXCR4 and
CCR5, respectively.4 These chemokines are involved in the production
of progenitor cells in the bone marrow, including endothelial progeni-
tor cells (EPCs) that facilitate endothelial cell function.5 Additionally, a
recently discovered subpopulation of T cells, angiogenic T (Tang) cells,
constitute the central cell cluster of EPC colonies6 and cooperate with
EPCs to facilitate vascular repair.7 Tang cells enhance the differentia-
tion of early EPCs and promote neovascularization and endothelial
repair, possibly through the secretion of proangiogenic cytokines,
such as vascular endothelial growth factor (VEGF), interleukin (IL)-8
and matrix metalloproteinases.6 Tang cells are characterized by co-
expression of CD31 and CXCR4, and are heterogeneous, since they
may express CD4 or CD8, and can co-express naïve and memory
markers.7
Since CXCR4 is the receptor for SDF-1α, we hypothesized that
DPP-4 inhibition may increase the frequency of circulating Tang
cells. Therefore, we determined the frequency of circulating Tang
cells in treatment-naive people with T2DM compared with healthy
controls, and assessed the effect of 26 weeks of DPP-4 inhibition
on the frequency of Tang cells and EPCs. The effect of DPP-4 inhi-
bition on circulating levels of SDF-1α, VEGF and IL-8 was also
determined.
2 | METHODS
2.1 | Study design and population
Samples included in this study were from the RELEASE trial
(NCT02015299). The study design and selection of participants
have been discussed previously.8 Participants were randomized in a
1:1 ratio to Linagliptin 5 mg once daily or a matching placebo for
26 weeks, stratified by age (30–49 vs. 50–70 years). Additionally, a
group of 19 healthy controls was included for measurement of
Tang cells. Healthy controls did not have diabetes, obesity or CVD
and were of similar age. Following the direct assessment of stan-
dard clinical laboratory variables, peripheral blood mononuclear
cells (PBMCs) were isolated and stored in liquid nitrogen for deter-
mination of Tang cell levels, and plasma was obtained from heparin-
ized blood.
2.2 | Tang cell analysis at inclusion and at
26 weeks
Frequencies of CD4+ and CD8+ Tang cell populations were analysed in
thawed PBMCs by flow cytometry. Briefly, cells were incubated with anti-
CD3-PerCP, anti-CD8-AF700, anti-CD25-PE, anti-CD45Ro-FITC, anti-
CCR7PE-Cy7, anti-CD31-PB and anti-CXCR4-BV605 (Biolegend, San
Diego and BD Biosciences, Vianen, Netherlands). Samples were analysed
on a BD™ LSR II flow cytometer and plotted using Kaluza v1.2 (Beckman
Coulter). Tang cells were expressed as percentages of total T cells (CD3+)
or as percentage of total CD4+ (gated as CD3+CD8− population) or of total
CD8+ cells (see Figure S1 for gating strategy). Based on the expression of
the surface molecules CCR7 and CD45Ro, a distinction was made in naive,
central memory (CM), effector memory (EM) and terminally differentiated
(TD) cell populations for both CD4+ and CD8+ subsets.
2.3 | EPC analysis at inclusion and at 26 weeks
For the EPC analysis 200 μL lithium-heparin blood was incubated with
anti-CD34-PE (clone 581; IQproducts), anti-CD133-APC (clone
AC133; Miltenyi Biotec) and anti-KDR/VEGFR-FITC (KDR-FITC; R&D
systems) or appropriate isotype controls (see Figure S1 for gating
strategy). Flow cytometry measurements were performed on a BD
Bioscience FACS Calibur flow cytometer, and analysed using Kaluza
analysis software.
2.4 | Enzyme-linked immunosorbent assay
Circulating levels of C-reactive protein, IL-8, VEGF and SDF-1α were
measured in plasma samples with Duosets enzyme-linked immunosor-
bent assays (R&D Systems) according to the manufacturer's instructions.
2.5 | Statistical methods
Means or medians were compared with independent sample Student
t-tests or Mann–Whitney U-tests, as appropriate, and discrete vari-
ables using chi-squared or Fisher's exact tests. An ANCOVA model
was constructed with change from baseline (ie, Tang cell percentages
or EPC levels) as a dependent variable, randomization group as fixed
factor and baseline levels as covariate. Variables were log transformed
when distribution was non-parametric. All analyses were performed
with SPSS (2013. IBM SPSS Statistics, Version 22.0). P values of <0.05
were taken to indicate statistical significance.
3 | RESULTS
Forty-five of the 50 screened participants with T2DM were random-
ized, 44 started treatment, and cell isolation was possible in 41
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participants (20 Linagliptin, 21 placebo). The median [interquartile
range (IQR)] age was 63 [56–67] years, median [IQR] BMI was
30.4 [27.4–37.2] kg/m2, median [IQR] diabetes duration was 1 [0–
3.5] years and the mean (SD) glycated haemoglobin (HbA1c) level was
45 (±4.8) mmol/mol. Baseline characteristics were well balanced
between groups. More baseline characteristics can be found in the
paper by De Boer et al.8 The median [IQR] age in the healthy control
group (n = 19, 63% male) was 56 [44–67] years.
Circulating Tang cell levels were significantly lower in people with
T2DM (median [IQR] 11.5 [9.4–17.8]%) compared with healthy con-
trols (median [IQR] 20.4 [16.6–27.3]%; P < 0.001 [Figure 1A]). This
was also seen in CD4+ T-cell subsets (median [IQR] 7.7 [4.3–10.8]%)
versus healthy controls (median [IQR] 13.2 [8.7–20.2]%; P < 0.01) and
in CD8+ T-cell subsets (median [IQR] 26.7 [19.4–38.1]% vs. 46.5
[32.1–55.2]%; P < 0.001 [Figure 1B,C]). There were no differences
between the T2DM and the healthy control group regarding percent-
ages CD4+-naive, EM and TD populations, while percentage of CM
cells was higher in people with T2DM (P = 0.02; Table 1). There were
significantly lower numbers of CD8+-naive cells in people with T2DM
compared to healthy controls (P = 0.005). Tang cells were specifically
present in naive fractions of both CD4+ cells and CD8+ cells. In people
with T2DM, percentages of Tang cells were reduced in the EM frac-
tion of both CD4+ cells and CD8+ cells (Table 1).
The frequency of total Tang cells (CD3+) increased in the
Linagliptin-treated (P = 0.029) but remained stable in the pla-
cebo-treated participants (Figure 1D,E). The change from base-
line differed significantly between Linagliptin and placebo
(median [IQR] +1.58 [–0.36 to 2.63]% vs. –0.24 [–0.74 to 0.52]%;
P = 0.016). After adjustment for baseline total Tang cells, the
trend remained present (P = 0.098). A similar increasing trend
was seen for CD8+ Tang cells (P = 0.052), but not for CD4+ Tang
cells (P =0.41). There were no significant changes in T-cell sub-
sets or Tang cells within these subsets after Linagliptin treatment
and placebo (data not shown). The change in the frequency of Tang
cells in Linagliptin-treated people with T2DM correlated negatively
with change in HbA1c (ρ = 0.39, P = 0.020); this was not observed
with placebo. Concomitantly, a rise in SDF-1α levels (median [IQR]
180 [126–238] pg/mL vs. 0 [0–2] pg/mL; P < 0.001 compared to
F IGURE 1 Frequencies of circulating Tang cells (CD31+, CXCR4+) in healthy controls (HC) and people with type 2 diabetes mellitus (T2DM)
in A, CD3+ cells and in B, CD4+ and C, CD8+ subsets measured by flow cytometry. Frequencies of circulating CD3+ Tang cells in people with type
2 diabetes mellitus (T2DM) before and after 26-week treatment with Linagliptin in D or with placebo in E. V1 = visit 1, baseline; V2 = visit 2,
week 26
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placebo) was seen in Linagliptin- compared to placebo-treated partici-
pants (Figure S2). No differences in levels of IL-8 and VEGF were
observed after Linagliptin or placebo treatment (data not shown).
A non-significant change after Linagliptin treatment was seen in
levels of EPCs (CD34+CD133+KDR+; P = 0.089) but was not seen for
placebo (Figure S3A). There was no correlation with Tang levels at
baseline (data not shown). EPC numbers from people with T2DM at
baseline correlated negatively with plasma levels of IL-8 (Spearman
ρ = −0.407, P = 0.008), and VEGF (ρ = −0.412, P = 0.008), and C-reac-
tive protein (ρ = −0.319, P = 0.043; Figure S3B).
4 | DISCUSSION
In the present study we showed that levels of Tang cells were signifi-
cantly reduced in treatment-naive people with T2DM compared to
age- and sex-matched healthy controls. Tang cells are particularly
found in naive subsets of both CD4+ cells and CD8+ cells. After
26 weeks of treatment with the DPP-4 inhibitor Linagliptin, a remark-
able rise in levels of SDF-1α was observed, coinciding with a signifi-
cant increase in CD3+ Tang cells and a trend for both CD4+ and CD8+
Tang cells, while Tang cells remained unchanged in placebo.
Tang cells are required for colony formation and differentiation of
early EPCs6 and, therefore, play an important role in endothelial
repair. Tang cells were found to be reduced in hypertension-related
cerebral small vessel disease9 and in people with active rheumatoid
arthritis.7 By contrast, levels were not reduced in people with sys-
temic lupus erythematosus, only in the disease controls, that is, people
with rheumatoid arthritis and people with CV risk factors,10 and were
increased in lupus nephritis in a later study.11 Miao et al 12 did
observe increased CD8+ Tang cell levels in people with systemic lupus
erythematosus, but not CD4+ Tang or total CD3+ Tang cells. These
data underline the complexity of Tang cells and suggest that several
diseases affect Tang cell levels.
Interestingly, we did not observe a correlation between levels of
Tang cells and EPCs. The loss of association between these two
angiogenic bone marrow-derived cells may indicate a disruption of
angiogenic repair by multiple disease-related processes, such as oxida-
tive stress and hyperglycaemia.13
The only other intervention study on Tang cell levels was in peo-
ple with rheumatoid arthritis,14 in which Tang cells increased signifi-
cantly after TNF-α blockade treatment, especially in those people
responding well to therapy.14 Our results, although obtained with a
completely different intervention, seem to be in line. Tang cell levels
TABLE 1 Percentages of T cells, CD4+ and CD8+ cells, subsets within CD4+ cells and CD8+ cells, and percentages of angiogenic T cells
within these subsets
Healthy control group, % Median [IQR] T2DM group, % Median [IQR] P
T cells 73.3 [63.3–75.9] 69.8 [62.3–77.3] 0.878
CD4+ cells 50.0 [42.1–57.3] 47.8 [41.0–53.0] 0.378
CD4+ Naive 39.2 [29.5–49.3] 36.0 [23.6–44.4] 0.242
CM 23.2 [17.1–32.7] 30.8 [22.8–38.4] 0.020
EM 26.7 [19.2–37.9] 25.2 [18.1–38.4] 0.612
TD 4.9 [2.8–7.3] 3.8 [2.2–6.3] 0.343
CD8+ cells 14.2 [11.4–20.4] 17.2 [11.7–24.9] 0.325
CD8+ Naive 32.0 [21.5–41.6] 17.6 [11.1–27.8] 0.005
CM 4.8 [3.0–6.0] 6.8 [4.3–9.3] 0.112
EM 29.3 [23.0–37.1] 33.0 [25.3–41.6] 0.167
TD 27.2 [19.0–40.8] 36.5 [22.0–43.0] 0.172
Tang cells 20.4 [16.6–27.3] 11.2 [9.4–17.8] <0.001
CD4+ cells 13.2 [8.7–20.2] 7.7 [5.3–10.8] <0.01
CD4+ Naive 10.4 [4.8–30.9] 15.8 [9.2–28.2] 0.409
CM 3.4 [2.5–8.0] 3.7 [2.3–5.9] 0.437
EM 4.8 [2.0–20.0] 1.6 [1.0–2.7] 0.0002
TD 9.5 [6.6–14.1] 8.2 [3.7–11.2] 0.143
CD8+ cells 46.5 [32.1–55.2] 27.7 [19.4–38.1] <0.001
CD8+ Naive 53.2 [28.4–85.6] 66.7 [51.1–78.4] 0.437
CM 21.9 [12.1–30.7] 18.2 [12.6–25.8] 0.387
EM 19.7 [12.9–65.2] 6.9 [4.8–11.5] <0.0001
TD 10.6 [8.4–12.7] 5.4 [3.3–7.4] 0.0003
Abbreviations: CM, central memory; EM, effector memory; IQR, interquartile range; TD, terminally differentiated; Tang cells, angiogenic T-cells; T2DM,
type 2 diabetes mellitus.
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increased following Linagliptin treatment and their rise correlated neg-
atively with HbA1c reduction. This supports the hypothesis that inter-
ventions on disease control stimulate bone-marrow Tang cell
recruitment, which may potentially have a beneficial effect on endo-
thelial repair.
The effects of DPP-4 inhibitors on EPC levels have been investi-
gated previously. A 4-day study with Linagliptin increased EPC levels
in people with T2DM,15 while 12-week treatment did not affect EPC
levels.16 In the first study, EPCs were defined as CD34+ CD133+ or
CD34+ KDR+, while in the second study EPCs were defined as CD34+
CD133+KDR+, as in the present study. Consequently, the duration, as
well as gating strategy could have played a role in the neutral effect of
Linagliptin in the present study and underlines the importance of mea-
suring EPCs by standardized markers. As mentioned, IL-8 and VEGF
levels were negatively correlated to EPC levels at baseline in people
with T2DM, and both IL-8 and VEGF levels were not changed after
Linagliptin treatment as well. We did see an increase in SDF-1α levels
in the Linagliptin-treated participants.
The present study has some limitations. First, the duration of
treatment was 6 months, so whether long-term changes would be
sustained or even be of a larger magnitude is unknown. Additionally,
it is unclear whether an increase in Tang cell levels would also result
in a significant reduction of CV events. Second, the trial lacked an
active control group, so whether Tang cell levels would increase after
treatment with other anti-hyperglycaemic drugs is also unclear. Fur-
thermore, we included recently diagnosed people with T2DM so it
might not be possible to extrapolate the findings to those with a lon-
ger diabetes duration or with advanced atherosclerotic disease.
In conclusion, Tang cell levels are decreased in people with T2DM,
and Linagliptin stimulates recruitment of these cells. This might indi-
cate the value of DPP-4 inhibitor treatment in the course of T2DM in
repairing endothelial damage of the micro- and microvasculature.
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